On Monday, Shares of General Electric Company (NYSE:GE), gained 0.78% to $25.95.
Nugget ice, the popular soft, chewable ice especially favored in the South and associated with restaurant chains and convenience stores, can now be enjoyed at home with the affordable Opal™ nugget ice maker from GE’s FirstBuild™.
Available to purchase starting July 28 through Indiegogo (www.nuggetice.com), Opal is a countertop nugget ice maker designed by the FirstBuild community and priced well below other presently accessible nugget ice makers. Early bird pricing starts around $399 or less, with future retail pricing predictable at $499. The ice maker will be shipped to Indiegogo contributors in mid-2016.
FirstBuild is a new model of manufacturing that challenges makers around the world to ideate and assist design innovations in home appliances. In March of this year, FirstBuild challenged its community to design a residential ice maker that would appeal to nugget ice enthusiasts. The design of Opal is a result of ideas generated by the maker community.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -2.55% to $64.30, during its last trading session.
Bristol-Myers Squibb Company (BMY) and AbbVie (ABBV) declared the European Medicines Agency (EMA) validated for review the Marketing Authorization Application (MAA) for Empliciti, an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in adult patients who have received one or more preceding therapies. The application was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. Bristol-Myers Squibb has projected the name Empliciti which, if approved by health authorities, will serve as the trade name for elotuzumab.
“The MAA validation marks a noteworthy milestone in Bristol-Myers Squibb’s mission to advance the science and impact the treatment of hematologic malignancies through our Immuno-Oncology leadership,” said Michael Giordano, MD, senior vice president, head of Oncology Development, Bristol-Myers Squibb. “We believe the CHMP’s acceptance for an accelerated assessment reflects the need for a new treatment option for multiple myeloma, a largely incurable disease. We are proud to be one step closer to bringing Empliciti to patients with relapsed or refractory multiple myeloma in Europe.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, The Walt Disney Company (NYSE:DIS), ended its last trade with -0.56% loss, and closed at $118.25.
Disney Store declared the all-new collections and Limited Editions set to launch at this year’s D23 EXPO 2015, Disney’s ultimate fan event held at the Anaheim Convention Center August 14–16. Located within the Disney Consumer Products Pavilion at D23 EXPO, the Disney Store shop will feature new and exclusive products showcased throughout more than 3,000 sq. ft. of retail space. New items celebrating everyone’s favorite characters will be unveiled each day throughout the weekend.
In addition to offering attendees the chance to shop special products not yet accessible to the general public, fans will also have the chance to meet the artists and designers who created these exciting new collections and be treated to the official Disney Store opening ceremony on Friday, August 14. During the ceremony, a special attendee will be chosen to “unlock imagination” at 9 a.m. alongside some of Disney’s most famous characters.
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates in five segments: Media Networks, Parks and Resorts, Studio Entertainment, Consumer Products, and Interactive.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
